DRONTAL CAT XL FILM-COATED TABLETS

Land: Irland

Sprog: engelsk

Kilde: HPRA (Health Products Regulatory Authority)

Køb det nu

Produktets egenskaber Produktets egenskaber (SPC)
13-05-2017

Aktiv bestanddel:

PRAZIQUANTEL PH. EUR., PYRANTEL EMBONATE

Tilgængelig fra:

Bayer Limited

ATC-kode:

QP52AA51

INN (International Name):

PRAZIQUANTEL PH. EUR., PYRANTEL EMBONATE

Dosering:

30/345

Lægemiddelform:

Tablets

Recept type:

CAM-Companion Animal Medicine

Terapeutisk gruppe:

Feline

Terapeutisk område:

Praziquantel, combinations

Terapeutiske indikationer:

Endoparasiticide

Autorisation status:

Authorised

Autorisation dato:

2004-08-06

Produktets egenskaber

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Drontal Cat XL Film-coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Film-coated tablet.
White to yellowish, ellipsoid, biconvex, unscored tablet.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of gastrointestinal roundworms and tapeworms:
_Toxocara cati, Toxascaris leonina, Dipylidium caninum,_
_Taenia taeniaeformis._
4.3 CONTRAINDICATIONS
Do not use simultaneously with piperazine compounds.
Not intended for use in kittens less than 6 weeks of age.
Until sufficient studies have been performed with this combination, do
not use during pregnancy.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Fleas serve as intermediate hosts for one common type of tapeworm –_
Dipylidium caninum_. Tapeworm infestation is
certain to re-occur unless control of intermediate hosts such as
fleas, mice etc is undertaken.
As a precautionary measure to prevent the establishment of_ E.
multilocularis_ in the UK or Ireland, it is recommended
that all cats entering the country be treated with praziquantel.
Each tablet contains:
ACTIVE SUBSTANCES
Pyrantel embonate
345
mg
Praziquantel
30
mg
EXCIPIENTS
Titanium dioxide E171 (colouring agent)
2.60 mg
For a full list of excipients see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_8_
_/_
_0_
_4_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_6_
_6_
_2_
_4_
_p_
_a_
_
                                
                                Læs hele dokumentet